Medios: Six Quarters of Margin Expansion, Then a Margin Miss

Larix Research · Market View · Medios AG (ILM1 · DE000A1MMCC8) is listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and is included in the SDAX selection index. No rating, no target. Disclosures at the end.

A chart and an income statement that disagree

Medios closed FY2025 with a clean beat. Consolidated revenue grew 10.4% to €2,078.7m (consensus €2,014m per five analysts, per IBES), Adjusted EBITDA pre rose 17.8% to €93.1m at a 4.5% margin (vs 4.2% prior), net income after taxes increased 22.4% to €15.4m, and reported earnings per share rose to €0.61 (vs €0.51). Reported operating cash flow rose materially — €52.3m on a working-capital-adjusted basis, with the cash-conversion rate improving into the high single digits.

The share price, in our reading, did not reward the print. The shares trade at €12.42, implying a market capitalisation of €318.99m on 25,505,723 shares outstanding and free float of 65.2%. Adding net debt of approximately €121m at year-end 2025 — equivalent to 1.3x FY2025 EBITDA pre of €93.1m, as disclosed in the AGM presentation deck of 10 June 2026 — gives enterprise value of approximately €440m. Against the FY2025 EBITDA pre of €93.1m, EV/EBITDA pre is approximately 4.7x; against the guided 2026 EBITDA pre midpoint of €98m, EV/EBITDA pre is approximately 4.5x. The 2025 print delivered on every operational metric, and the equity has not rerated.

The income statement says acceleration. The market is pricing something else.

The derating Medios was drafted into

Three things happened to the equity narrative between the FY2024 print (March 2025) and the FY2025 print (March 2026) that explain the gap between the operational result and the price.

First, the previous CEO departed. Matthias Gärtner stepped down at the end of 2025 after a tenure in which the EBITDA pre margin expanded from approximately 2% to 4.5% — a real operational story — but the share price never rerated to reflect it. The departure was announced alongside the search for a successor; Thomas Meier, the former CEO of Bachem, was appointed on 3 November 2025 to take office on 1 February 2026. Ceban Group's integration and the new CEO's transition were the operating narrative through H2 2025 and into Q1 2026.

Second, Q1 2026 disappointed — and the segment breakdown matters more than the headline. The print on 12 May 2026 showed revenue of €527.6m (+8.9%) but EBITDA pre of €21.2m, down 7.9% year-on-year at a margin of 4.0% (vs 4.1% prior). Adjusted EPS fell to €0.44 from €0.46. The segment-level disclosure in the AGM presentation deck of 10 June 2026 reframes the story: Pharmaceutical Supply margin held at 2.9% (vs 3.0% prior year, a 10 bp slip); Patient-Specific Therapies margin compressed to 8.9% from 11.3% (-240 bps); and International Business margin fell to 14.7% from 18.4% (-370 bps). The aggregate margin compression was not, on this read, a wholesale-segment pricing story — it was a compounding-segments story, which is materially worse for the thesis. Patient-Specific Therapies and International Business are the segments that are supposed to pull the consolidated margin toward the 5-6% range; if their margins are compressing in tandem with wholesale, the bull case loses its engine. Management has identified the same dynamics — price pressure on certain products, shifts in product mix, one-time costs, and broader logistics and energy cost inflation; the year-earlier quarter also benefited from a €1.4m one-off gain on the sale of a Dutch pharmacy that did not repeat. Management framed the miss as transitional and confirmed the full-year guidance, but the print was the second EBITDA miss in three quarters and the third consecutive quarter of margin compression (4.6% in 9M 2025 → 4.5% FY 2025 → 4.0% Q1 2026) once the base effect is netted out.

Third, the new CFO took office in the middle of the print. Stefan Bauerreis, the new CFO with a background at Stabilus and Schaeffler, started on 15 April 2026 — four weeks before the Q1 release. A new CEO since February, a new CFO since mid-April, and a margin print that broke the multi-quarter expansion pattern: the market reasonably asks whether the new management team inherits a margin problem that is structural rather than transitional, and whether the prior CFO's replacement is part of the answer or part of the symptom.

The combination of these three things — leadership transition, margin print, narrative ambiguity — is what produced the derating. The market is not, on our reading, repricing the business model. It is repricing the next-twelve-months execution against the prior trajectory.

What specialty pharma distribution actually sells

Medios is a regulated pharmaceutical supply-chain operator with three reporting segments, all of which earn their margin from regulatory access, supplier relationships, and physical handling of medicines — not from software or platform economics. The segments are:

• Pharmaceutical Supply. Wholesale distribution of specialty pharmaceuticals in Germany and adjacent markets. FY2025 external revenue €1,688.8m (+6.9%); EBITDA pre €52.5m (+5.1%) at a segment margin of approximately 3.1%. Serves approximately 4,200 partner pharmacies (940 of them in Germany) and more than 200 hospital pharmacies across Europe, plus the company's own production facilities and the 24 Medsen-branded pharmacies in the Netherlands.
• Patient-Specific Therapies. Manufacturing of compounded, patient-individualised medications (sterile and non-sterile preparations, including for oncology, ophthalmology, and other complex therapies) under GMP at eight GMP labs in Germany and the Netherlands. FY2025 external revenue €220.1m (+3.0%); EBITDA pre €22.2m (-4.6%). Ten GMP-compliant facilities in total. Margins here are structurally higher than wholesale — approximately 10% segment EBITDA pre margin — because the regulatory and technical capability required to compound patient-individualised preparations is a binding constraint that limits new entrants.
• International Business. Ceban Group, acquired and consolidated from June 2024, operating compounding and distribution in the Netherlands, Belgium, and Spain. FY2025 external revenue €169.2m (vs €88.8m in the six months from June to December 2024, so the full-year comparable is roughly double); EBITDA pre €29.1m (vs €16.3m for the partial period), implying a run-rate EBITDA pre of approximately €35-40m at the segment margin of approximately 17-20%.

The economic substance is straightforward. Each segment earns a margin by being the licensed, regulated intermediary between a pharmaceutical manufacturer and a dispensing point — a hospital, a partner pharmacy, a patient-specific prescription. The moat is regulatory: every step of the chain (wholesale licence, GMP compounding licence, GDP logistics, controlled-substance handling) is a regulated activity with high switching costs and a small universe of licensed counterparties. None of this is exposed to the kind of AI disintermediation that has driven software-valuation derating in 2025-26; the regulatory and physical infrastructure does not move on inference cost. The same argument we made on SMG applies in a different register: Medios sells access, not capability.

On top of the regulatory infrastructure sits a workflow-integration layer. Medios Digital GmbH, a wholly owned subsidiary founded in 2017, operates mediosconnect — a digital ordering and billing portal connecting doctors, health insurers, and specialized partner pharmacies for complex and individualized drugs. The platform was live in seven German federal states by 2023, with monthly order volumes growing approximately 22% year-on-year, and is positioned to integrate the German national e-prescription (E-Rezept) system as that rollout matures. The 2026 Fokusaktivitäten programme adds ERP/SAP (S/4HANA) implementation at Medios Pharma and a broader digital roadmap for cross-business integration, including the Ceban / Medsen pharmacies acquired in 2024. This is not a software-margin story — mediosconnect is workflow infrastructure, not platform economics — but it embeds partner pharmacies in the ordering process in a way that raises switching costs and reinforces the regulatory moat. The same point applies to the E-Rezept integration: a national digital-prescription standard would, if anything, harden the position of the platforms already wired into the workflow.

The reference-class for the multiple is therefore not SaaS, not vertical software, and not a marketplace. The comparable companies are Fagron (specialty pharma compounding in the Netherlands and globally; FY2025 REBITDA €192.9m at a 20.3% margin), Phoenix Group (European pharma wholesale leader, private), McKesson and Cencora (US specialty and broad-line wholesale), and the broader set of specialty compounding platforms. Fagron, as the publicly-traded peer most directly comparable to Medios' compounding business, is the cleanest read on the multiple: at the time of the FY2026 guidance reaffirmation, Fagron traded at approximately 9x forward EV/EBITDA on FY2026 estimates, against Medios' ~4.5x. The implied re-rating case is the article's central question.

The bull case, steelmanned

Because the bear case on a German small-cap with a margin miss and a new management team is easy to construct — and because the bear case is, in our reading, partial — we steelman the bull first. Four pillars.

One, the multiple-expansion arithmetic is concrete. At ~4.5x forward EV/EBITDA on FY2026 guidance midpoint, Medios sits well below a market multiple for low-growth distribution (around 5-6x) and well below a multiple for compounding-led specialty pharma platforms (Fagron at ~9x, plus optionality from the Ceban integration that should close the margin gap over time). If the EBITDA pre margin reaches 4.8% on FY2026 revenue of €2.0-2.12bn (in line with guidance), and the market moves to a 7x multiple — well below Fagron's 9x and in the middle of the comp range — the equity roughly doubles on multiple expansion alone. A move to Fagron parity implies a 2x. The cash-flow yield — approximately 16% on FY2025 reported operating cash flow of €52.3m at the current market capitalisation of €319m, and 13-14% after €8.3m of capex — combined with leverage at 1.3x EBITDA pre, gives the equity a meaningful tail: at the current price, the company could fund a meaningful buyback with current free cash flow and still reduce leverage. The cash-flow tail is qualified by the working-capital caveat below, but the arithmetic of the multiple versus the comp set is concrete. None of this is speculative; it is the arithmetic of where the multiple sits versus where comparable businesses trade.

Two, the operating track record of the new CEO is one of the strongest in the European small-mid-cap universe. Thomas Meier ran Bachem from January 2020 through December 2025. Over that period, Bachem's reported EPS rose from CHF 0.78 (2019) to CHF 1.98 (2025) — a 17% per-annum compound, over six years that included the COVID-driven CDMO boom and the subsequent normalisation. Bachem is a Swiss-listed specialty CDMO with FY2024 revenue of approximately CHF 530m and a market capitalisation that at the time of his departure exceeded €3bn at a trailing EV/EBITDA of approximately 22x. The argument for Meier at Medios is not that he will replicate Bachem (the businesses are different), but that he has demonstrated an ability to compound operating leverage at a specialty-pharma-adjacent business, including through periods of execution pressure and integration work. That is the relevant track record for a CEO who is inheriting a 4.5% EBITDA margin business and a management-team transition at the same time. Bauerreis's resume — CFO at Stabilus, senior finance roles at Schaeffler — is the right profile for the operational and capital-allocation work that the equity will demand.

Three, the segments are more durable than the Q1 print suggests, with a meaningful caveat. Pharmaceutical Supply is a wholesale-distribution business with structurally low margins (3.1% segment EBITDA pre) and structurally high working-capital absorption — the issue the FY2025 cash flow statement exposed (the working-capital-adjusted gross cash flow grew 26% per the management commentary, but reported operating cash flow fell 29% to €52.3m because of working-capital absorption). This is not a margin-expansion story; it is a working-capital-efficiency story, and the new CFO's job is to convert that improvement into reported operating cash flow that supports a buyback or a re-leveraging. Patient-Specific Therapies and International Business together generated approximately €51m of segment EBITDA pre on approximately €389m of revenue (13% segment margin) — and these are the segments where the compounding-led margin profile can pull the consolidated margin to the 5-6% range over a three-to-five-year horizon if management executes. The Q1 print bears on the wholesale segment's pricing pressure and the timing of cost normalisation; on the segment-level evidence, however, it also bears on the compounding segments, which is the single most important data point added by the AGM disclosure. The management response — the Capital Master Plan and the operational excellence programme referenced in the AGM presentation — is a coherent attempt to address this; whether it works is a Q2 / H1 print question.

Four, management is buying at current prices. The new CEO Thomas Meier acquired 13,638 shares at €16.00 on 1 February 2026 — his first ownership event as CEO, structured as a transfer of treasury shares as part of his board compensation, valued at €218,208. Board member Christoph Prußeit bought 4,000 shares at €14.96 on 21 January 2026 in the open market, above the current price. The current insider cycle is worth reading against the prior one: in December 2021, then-CEO Matthias Gärtner, Prußeit, and COO Mi Young Miehler each sold 100,000 / 50,000 / 100,000 shares at €35.00-35.50 — the all-time high — and re-bought the same size blocks at €7.00 within weeks, the cleanest insider bottom-call in the German mid-cap universe over the last decade. The current buying at €14-16 sits well below the prior sale prices and is consistent with management treating current levels as the entry of a new cycle. The CEO is, in any event, now in the money above €16 — a self-aligned signal that the equity rerates from here.

The bull case, then, is not that Q1's miss is a non-event. It is that the miss is a wholesale-segment timing issue and that the multiple is set by the compounding segments and the new management's ability to compound them. The trade on this reading is to hold through the management transition and own the multiple expansion as the FY2026 numbers roll in.

What we would actually worry about

Five risks are real, and three of them are specific to Medios rather than to the European specialty pharma distribution category.

One, the Q1 margin trajectory has to stabilise before the multiple rerates. The Q1 EBITDA pre margin of 4.0% is the lowest print in six quarters and follows the 9M 2025 margin of 4.6%, the FY2025 margin of 4.5%, and the Q4 2025 margin (which we estimate at approximately 4.4% from the disclosure of the segment dynamics). A second consecutive quarter of margin compression would shift the thesis from "wholesale-segment pricing is a transitional pressure that resolves in H2" to "the consolidated margin has plateaued at 4.5%, not 4.8%." The FY2026 cost guidance from the AGM presentation — personnel costs up approximately 9%, other operating costs down approximately 7%, per the management commentary on the FY2026 plan — is, on its face, a modest net headwind to margins, since personnel is the larger cost category. Management has flagged gezielte Maßnahmen zur Optimierung der Kostenstruktur in den Segmenten International Business und Patient-Specific Therapien — targeted measures to optimise the cost structure in the International Business and Patient-Specific Therapies segments — which is the right framing but also an explicit acknowledgement that the run-rate margin in the compounding segments is not yet at the target. The Fokusaktivitäten 2026 outlined in the AGM deck — the explicit articulation of the management response — are organised around four pillars: (i) One Team Medios, harmonisation of business and planning processes for the compounding and pharma-supply businesses, plus the introduction of ERP/SAP (S/4HANA) at Medios Pharma; (ii) Operative Exzellenz, network optimisation on a Capital Master Plan, with business integration along a digital roadmap; (iii) Beschleunigung des organischen Wachstums, accelerating compounding-segment growth with existing and new customers, including the capture of market trends and regulatory adaptations; (iv) Selektive M&A-Aktivitäten, value-adding add-on acquisitions only. The plan reads as a coherent attempt to address the segment-level margin compression that the Q1 print exposed; whether it delivers against the FY2026 guidance is a H1 and Q3 print question. The Q2 print on 12 August 2026 is the next data point; the H1 print in mid-September is the verdict on whether the full-year guidance holds.

Two, the Ceban integration is still being absorbed. Ceban has been consolidated for approximately 18 months. The full-year 2025 segment performance (€169m revenue, €29m EBITDA pre) is the first full year in the consolidated numbers, and the segment margin (approximately 17%) is lower than the standalone Ceban margin implied by the historical disclosures. Management has flagged "targeted measures to optimize the cost structure in the International Business and Patient-Specific Therapies segments" in the Q1 commentary — a reasonable signal of integration work, but also an admission that the run-rate margin is not yet at the target. If integration delays or working-capital absorption accelerates, the International Business segment could be a margin drag in 2026 rather than a margin contributor.

Three, working-capital absorption is the structural cash-flow risk, and the FY2025 print is the cleanest evidence. Specialty pharmaceutical distribution is a high working-capital-intensity business — every euro of revenue requires a roughly equivalent euro of inventory and receivable. The FY2025 cash-flow statement showed reported operating cash flow of €52.3m, down 29% from €73.7m in FY2024, with the working-capital-adjusted gross cash flow up 26% to a roughly €93m figure (per the management commentary on the FY2025 results call). The reconciliation is straightforward: approximately €40m of working-capital absorption in FY2025 explains most of the gap. A return to working-capital absorption in FY2026 — which would happen organically if revenue grows faster than inventory turns — would compress the cash that the equity story says is available for buybacks. Net debt at year-end 2025 was 1.3x EBITDA pre, down from 1.7x at year-end 2024; the room for absorption is real but not unlimited, particularly given the €13.5m already deployed in the July 2025 buyback at €12.50 per share (1,000,000 shares at a 9.3% premium to the five-day VWAP, per the AGM presentation).

Four, the share-price weakness is its own problem, and the AGM just opened the door. A sub-€15 share price on a ~25.5m share count means a market capitalisation below the cash-generating capacity of the business, and the consequence is that any meaningful acquisition the company might attempt would be value-destructive in equity terms. The way out of this is either a re-rating (the bull case) or a buyback that lifts the share price enough to restore M&A optionality. The annual general meeting on 10 June 2026 voted on item 10 of the agenda, a renewal of the authorisation to acquire treasury shares with exclusion of subscription rights — the immediate legal mechanism for a buyback. Management did not, in the AGM presentation, commit to a buyback programme, but the authorisation is in place. The €12.50 reference price from the July 2025 buyback — a 9.3% premium to the five-day VWAP — is the most recent evidence of what management is willing to pay for its own equity; at the current €12.42, a buyback at the same reference would be effectively at-the-market. The 2026 guidance slide from the AGM presentation is explicit on the M&A question: Keine M&A im Budget berücksichtigt — no M&A is reflected in the FY2026 budget — and the Fokusaktivitäten 2026 frame M&A as wertsteigernde Add-on-Akquisitionen only, value-adding bolt-on acquisitions. The market capitalisation is, on management's own framing, too small to support any deal that would be value-adding rather than value-destroying in equity terms. The new CFO's first signal on capital allocation — expected around the H1 print — will determine whether the equity is in a position to compound.

Five, the Fagron comparison is the cleanest comp but it is not the only comp. Phoenix Group (private) is the European wholesale leader and would trade at a different multiple than a compounding platform; McKesson and Cencora are US broadline wholesalers at ~10-12x EBITDA, more reflective of the wholesale side of Medios than the compounding side. A pure-play on the compounding business would trade closer to Fagron; a pure-play on the German specialty wholesale would trade closer to Phoenix's historical multiple of approximately 7x. The consolidated entity is somewhere between, and the multiple the market assigns should reflect the segment mix that the consolidated income statement produces. If the compounding segments fail to grow into their potential, the consolidated multiple compresses toward the wholesale end of the range.

The trade the market is offering

Strip it to the exchange being proposed. At ~4.5x forward EV/EBITDA on guidance midpoint, the market is pricing a German specialty pharma distribution business whose Q1 print broke a six-quarter margin-expansion pattern, in the middle of a leadership transition, with the FY2026 guidance intact but not yet tested by a second-quarter print. The audited record shows 10.4% revenue growth and 17.8% EBITDA pre growth in FY2025, a margin expansion of 30 basis points, a 22.4% increase in net income, a working-capital-adjusted gross cash flow up 26%, and a balance sheet that supports a meaningful buyback. The reference class — Fagron at ~9x, Phoenix historically at ~7x — points to a higher consolidated multiple than the market is currently paying. The AGM of 10 June 2026 voted to carry the FY2025 distributable profit — Bilanzgewinn — of €111.4m (vs €81.3m prior, +37.1%) forward in full, consistent with the growth-investment posture that the bull case rests on.

Where the street sits is the cleanest anchor for the multiple-expansion case. The five sell-side analysts covering Medios — Berenberg, Warburg, Kepler Cheuvreux, Hauck & Aufhäuser, and Deutsche Bank — carry an average target of €24.50, with a range from €18 (Deutsche Bank) to €32 (Berenberg, most recently revised from €35 in the prior cycle). At €12.42, the consensus implies approximately +97% upside on a twelve-month horizon. Our arithmetic puts the multiple-expansion case at roughly +100% to +120% on a re-rating alone to a 7-9x range; the street sees roughly twice that on a bull-case compounding outcome, with the downside target (Deutsche Bank at €18) implying a +45% floor. The market is pricing a structural discount the consensus does not recognise; or the consensus is wrong and the equity is appropriately priced for the segment-level compression the Q1 print exposed; or both. The Q2 and H1 prints will resolve the question.

The risks that remain — Q1 margin trajectory, Ceban integration, working-capital absorption, share-price-driven M&A restriction, segment-mix-dependent multiple — are real and specific. None of them is the risk the derating is pricing, which is "the FY2026 guidance will not be met." If the Q2 and H1 prints hold the guidance, the multiple does most of the work. If they do not, the operating question replaces the multiple question, and the analysis becomes harder.

We publish no rating on Medios and hold no position. The trade, if there is one, is to wait for the H1 print, watch the segment mix in the disclosure, and reassess at the Q3 print in November. The framework above will determine which side of that consensus you want to be on.

Sources and method

Medios is covered by sell-side research; this note is a market commentary, not an initiation of coverage, and contains no recommendation, rating, or price target. Figures are drawn from the audited consolidated financial statements of Medios AG for the year ended 31 December 2025 (published 26 March 2026, auditor's opinion reviewed in the annual report), the Q1 2026 interim release dated 12 May 2026, the FY2025 results presentation dated 26 March 2026, the Q1 2026 results presentation dated 12 May 2026, the AGM 2026 presentation deck filed 9 June 2026 for the annual general meeting of 10 June 2026 (for segment-level Q1 2026 dynamics, buyback execution, leverage at year-end 2025, FY2026 cost guidance, the Fokusaktivitäten 2026 programme, and the Bilanzgewinn allocation), the company's IR materials and corporate calendar (for the directors' dealings disclosed in February 2026), the Bachem 2025 annual report (for the CEO track-record reference), the Fagron FY2025 results and 2026 guidance disclosures (for the multiple-comparison reference), the May 2026 Fact Sheet from MarketScreener (for the shareholder structure and the consolidated sell-side consensus target range of €18-32), and the German voting-rights notifications published via BaFin. Specialty-pharmacy multiple ranges are drawn from FOCUS Bankers' 2026 report on specialty pharmacy transaction multiples. We have had no contact with the company or with Paladin Asset Management prior to publication.